A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

Part of paid clinical trials in Greenville, South Carolina.

Sponsor
Kyowa Kirin Co., Ltd.
Study ID
NCT07629726
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • KK2430 — DRUG
    KK2430 administered intravenously

Study Details

KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Apr 30, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
72 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: 2430-001 Part 1
    KK2430 intravenous administration (including placebo)

Primary Outcome Measure

Dose Level Toxicity (DLT) [ Time Frame: Endpoint 28 days after first dose ]

Central Contacts

Locations (1)

FacilityCityStateZIP
Prisma HealthGreenvilleSouth Carolina29605

Find similar trials in Greenville, SC

By research site
Prisma Health· Greenville, SC

Related Studies